Literature DB >> 15555543

The tumor protein D52 family: many pieces, many puzzles.

Rose Boutros1, Susan Fanayan, Mona Shehata, Jennifer A Byrne.   

Abstract

Tumor protein D52-like proteins are small coiled-coil motif bearing proteins which are conserved from lower organisms to human. The founding member of the family, human D52, has principally attracted research interest due to its frequent overexpression in cancer, often in association with D52 gene amplification. This review summarises published literature concerning this protein family since their discovery, which is highlighting an increasing diversity of functions for D52-like proteins. This in turn highlights a need for more comparative functional analyses, to determine which functions are conserved and which may be isoform-specific. This knowledge will be crucial for any future manipulation of D52 function in human disease, including cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15555543     DOI: 10.1016/j.bbrc.2004.10.112

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  38 in total

1.  MAL2 selectively regulates polymeric IgA receptor delivery from the Golgi to the plasma membrane in WIF-B cells.

Authors:  Julie G In; Pamela L Tuma
Journal:  Traffic       Date:  2010-05-07       Impact factor: 6.215

2.  Keratin 19 expression correlates with poor prognosis in breast cancer.

Authors:  Nuzhat N Kabir; Lars Rönnstrand; Julhash U Kazi
Journal:  Mol Biol Rep       Date:  2014-08-26       Impact factor: 2.316

3.  Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.

Authors:  M D Landis; D D Seachrist; F W Abdul-Karim; R A Keri
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

4.  Tumor protein D52 controls trafficking of an apical endolysosomal secretory pathway in pancreatic acinar cells.

Authors:  Scott W Messenger; Diana D H Thomas; Michelle A Falkowski; Jennifer A Byrne; Fred S Gorelick; Guy E Groblewski
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-07-18       Impact factor: 4.052

5.  Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting.

Authors:  Christoph Biesemann; Mads Grønborg; Elisa Luquet; Sven P Wichert; Véronique Bernard; Simon R Bungers; Ben Cooper; Frédérique Varoqueaux; Liyi Li; Jennifer A Byrne; Henning Urlaub; Olaf Jahn; Nils Brose; Etienne Herzog
Journal:  EMBO J       Date:  2014-01-10       Impact factor: 11.598

6.  Identification of PLP2 and RAB5C as novel TPD52 binding partners through yeast two-hybrid screening.

Authors:  Hamideh Shahheydari; Sarah Frost; Brian J Smith; Guy E Groblewski; Yuyan Chen; Jennifer A Byrne
Journal:  Mol Biol Rep       Date:  2014-03-07       Impact factor: 2.316

7.  DNA Vaccines for Prostate Cancer.

Authors:  Douglas G McNeel; Jordan T Becker; Laura E Johnson; Brian M Olson
Journal:  Curr Cancer Ther Rev       Date:  2012-11-01

8.  Tumor protein D54 is a negative regulator of extracellular matrix-dependent migration and attachment in oral squamous cell carcinoma-derived cell lines.

Authors:  Yoshiki Mukudai; Seiji Kondo; Atsushi Fujita; Yasuto Yoshihama; Tatsuo Shirota; Satoru Shintani
Journal:  Cell Oncol (Dordr)       Date:  2013-03-26       Impact factor: 6.730

9.  MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Authors:  Jennifer A Byrne; Sanaz Maleki; Jayne R Hardy; Brian S Gloss; Rajmohan Murali; James P Scurry; Susan Fanayan; Catherine Emmanuel; Neville F Hacker; Robert L Sutherland; Anna Defazio; Philippa M O'Brien
Journal:  BMC Cancer       Date:  2010-09-17       Impact factor: 4.430

10.  microRNA-503 suppresses the migration, proliferation and colony formation of prostate cancer cells by targeting tumor protein D52 like 2.

Authors:  Yuhua Chi; Feng Ding; Wenjie Zhang; Lifa Du
Journal:  Exp Ther Med       Date:  2017-10-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.